Showing results (261-270 of 1,645) with videos related to
Sort By:
Pageof 165
Therapeutic Innovation & Regulatory Science|December 1, 2020
Assessing the Scope and Predictors of Intentional Dose Non-adherence in Clinical TrialsKenneth Getz, Zachary Smith, Laura Shafner, et al.Therapeutic Innovation & Regulatory Science|December 1, 2020
Benchmarking the Vendor Qualification ProcessKenneth Getz, Michael Wilkinson, Jay Turpen, et al.Therapeutic Innovation & Regulatory Science|October 30, 2020
Pharma Collaboration for Transparent Medical Information (phactMI™) Benchmark Study: Results of Organizational Structure and Resourcing of Medical Information Services in Support of Building Departmental StrategiesKirstie Marasigan, Sara Doshi, Stacey FungTherapeutic Innovation & Regulatory Science|November 24, 2020
Biosimilars in Malaysia: Regulatory Framework, Approved Products, and Adverse EffectsNoraisyah Mohd Sani, Zoriah Aziz, Adeeba KamarulzamanTherapeutic Innovation & Regulatory Science|January 23, 2020
Giving Voice to Clinical Study Participants: Development and Deployment of Sequential Patient Experience Surveys for Global Clinical StudiesElizabeth Manning, Mitch Herndon, Wendy Frye, et al.Therapeutic Innovation & Regulatory Science|September 5, 2020
Quality Tolerance Limits: Framework for Successful Implementation in Clinical DevelopmentRuma Bhagat, Lukasz Bojarski, Soazig Chevalier, et al.Therapeutic Innovation & Regulatory Science|November 9, 2020
phactMI Benchmarking Survey on Content Development and Inquiry ManagementJacqueline Byun, Jin Ah Jong, Amina Gangat, et al.Therapeutic Innovation & Regulatory Science|September 22, 2020
Analysis of Pediatric Drug Approval Lag in JapanEiji Ueyama, Masayuki Kaneko, Mamoru NarukawaTherapeutic Innovation & Regulatory Science|June 8, 2021
An FDA Analysis of Inspected Entities After Receiving Official Action Indicated Letters for Good Clinical Practice ViolationsMiah Jung, Rachelle M Swann, Michelle S Anantha, et al.Therapeutic Innovation & Regulatory Science|June 10, 2021
Factors Influencing Classifications of Safety Specifications in a Risk Management Plan for Antineoplastic Agents Approved in Japan: A Review and Descriptive AnalysisAsami Ezaki, Akihiro Hirakawa, Hideki Hanaoka, et al.Pageof 165